M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
Clinical-stage biotechnology company Arvinas Inc (Nasdaq:ARVN) and biopharmaceutical company Pfizer Inc (NYSE:PFE) have submitted a New Drug Application to the US Food and Drug Administration (FDA) for vepdegestrant, an investigational treatment targeting estrogen receptor-positive (ER+)/human...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search